Akebia Therapeutics (AKBA) Non-Current Debt (2019 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Non-Current Debt of $36.4 million for Q1 2026, down 21.75% year-over-year from $46.5 million in Q1 2025, and down 24.57% quarter-over-quarter from $48.2 million in Q4 2025.
Akebia Therapeutics (AKBA) Non-Current Debt (2019 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Non-Current Debt for 8 consecutive years, with $36.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Debt fell 21.75% year-over-year to $36.4 million; the TTM figure through Mar 2026 stood at $36.4 million (down 21.75% YoY), while the FY2025 annual figure was $48.2 million, up 24.7% from the prior year.
- Non-Current Debt retreated to $36.4 million in Q1 2026 per AKBA's latest filing, from $48.2 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $98.2 million in Q2 2022 and bottomed at $17.2 million in Q4 2023.
- Historically, Non-Current Debt has averaged $41.6 million across 5 years, with a median of $38.2 million in 2024.
- Annual changes were most pronounced in 2023 — Non-Current Debt tumbled 81.17% — and 2024, when it surged 125.18%.
- Akebia Therapeutics' Non-Current Debt stood at $34.1 million in 2022, then plunged by 49.58% to $17.2 million in 2023, then surged by 125.18% to $38.7 million in 2024, then rose by 24.7% to $48.2 million in 2025, then slipped by 24.57% to $36.4 million in 2026.
- Business Quant data shows AKBA's Non-Current Debt at $36.4 million in Q1 2026, $48.2 million in Q4 2025, and $47.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 130.00 Mn |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn | 49.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 49.56 Mn |
| Mar 31, 2026 | 36.40 Mn |
| Dec 31, 2025 | 48.25 Mn |
| Sep 30, 2025 | 47.64 Mn |
| Jun 30, 2025 | 47.06 Mn |
| Mar 31, 2025 | 46.51 Mn |
| Dec 31, 2024 | 38.69 Mn |
| Sep 30, 2024 | 38.36 Mn |
| Jun 30, 2024 | 38.03 Mn |
| Mar 31, 2024 | 30.15 Mn |
| Dec 31, 2023 | 17.18 Mn |
| Sep 30, 2023 | 34.61 Mn |
| Jun 30, 2023 | 18.49 Mn |
| Mar 31, 2023 | 26.30 Mn |
| Dec 31, 2022 | 34.08 Mn |
| Sep 30, 2022 | 65.95 Mn |
| Jun 30, 2022 | 98.16 Mn |
| Sep 30, 2021 | 97.23 Mn |
| Jun 30, 2021 | 96.92 Mn |
| Mar 31, 2021 | 96.61 Mn |